NR1D1 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-02 and is reviewed periodically as new material appears.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
=== Background and theme === On January 9, 2020, American Horror Story was renewed for up to a thirteenth season. On December 5, 2018, Ryan Murphy said the witches from Coven would return in a future season. On July 28, 2026, Murphy announced in an interview with Entertainment Tonight that the season, officially titled 13, would consist of 13 episodes, and while the season would revisit Coven, it was not a direct sequel. He desribed it as an Avengers-style crossover between "all the seasons", with characters coming together "to defeat the ultimate evil", and added that he spent years writing it. Leslie Grossman explained that the series was set in one universe with different timelines, which "intersect in a way that makes sense". The theme of the number 13 was announced alongside the title. The show's official FX page for the season reads: "FX's American Horror Story ... returns for an unrivaled 13th installment that will do justice to everyone's most feared number. ... Which iconic horrors will return to haunt the hallowed halls of 13 and what new terrors await? Light your candles, draw your pentagrams and prepare for a supreme surprise." In August 2026, Murphy revealed he would direct an episode, for the first time since "Checking In" (2015). In September 2026, he said that the crossover with Scream Queens was planned to be included in the season, but it was scrapped after the departure of Ariana Grande, who was supposed to reprise her role as Chanel #2.
==== Tandem models ==== Between 1958 and 1973, HVEC manufactured 55 tandem accelerators in four progressively larger models. Each generation opened new experiments with heavier ions, higher energies, and previously inaccessible nuclear reactions. The EN model became the production workhorse. First installed at Chalk River in 1959, it was the first large accelerator to use pure sulfur hexafluoride as insulating gas, which allowed higher voltages in a smaller tank. Its commercial viability depended on two developments: sufficiently intense negative ion sources (developed at Chalk River and Wisconsin) and HVEC's invention of the inclined-field acceleration tube, which solved the voltage breakdown problem that had plagued earlier long tubes. HVEC built 30 EN units for institutions across seven countries. At Chalk River, researchers used the EN to discover quasi-molecular states—transient configurations where colliding nuclei briefly orbit each other before separating. The FN model ("King") extended terminal voltages to 9 megavolts in its "Super FN" variant. The first went to Los Alamos in October 1963. HVEC sold 17 FN units to laboratories including Rutgers, Florida State, Stanford, and national research institutes in France and Romania. The MP model ("Emperor"), a much larger model commissioned by the Atomic Energy Commission in 1962, employed an "open truss" column structure—beams fabricated from alternating steel and glass plates bonded with epoxy—that supported a substantially larger terminal while maintaining electrical insulation.
== Pharmacology == Omeprazole irreversibly blocks the enzyme system on parietal cells that is needed for the secretion of gastric acid. It is a specific H+/K+ATPase inhibitor. This is the enzyme needed for the final step in the secretion of gastric acid.
=== October === 1 October – Prime Minister Rishi Sunak announces £20m of levelling up funding to help regenerate seven Scottish towns that are described as having been overlooked. 2 October – ScotRail begins a six months trial during which peak time train fares are scrapped. 3 October – Aberdeen City Council says that reinforced autoclaved aerated concrete (RAAC) is likely to have been used in hundreds of properties in the city. 4 October – Police Scotland pays £60,000 compensation to four traffic officers told to shave off their beards before the force implemented its delayed proposals for a clean shaven policy. 5 October – Labour's Michael Shanks wins the Rutherglen and Hamilton West by-election. 6 October – Police Scotland scraps plans to recruit an extra 200 officers in January 2024 as it attempts to save costs following a projected overspend of £19m. 7 October – The Met Office issues an amber weather alert for heavy rain in Scotland, while roads and train services are disrupted by flooding. Ten people are airlifted to safety after heavy rain causes landslides on two roads in Argyll. 9 October – Bernard Cowan, a grandfather who grew up in the Glasgow area, is confirmed as one of the people killed during a series of attacks launched by Hamas against Israel on 7 October. Humza Yousaf, the First Minister of Scotland, condemns the attacks and expresses concern for his in-laws, who are "trapped" in Gaza after travelling there to visit relatives. The Scottish Medicines Consortium (SMC) approves the weight loss drug semaglutide for use by NHS Scotland.
Each component interacts with the stationary phase in a different manner depending upon its polarity and hydrophobicity. In reverse phase HPLC, the solute with the greatest polarity will interact less with the stationary phase and spend more time in the mobile phase. As the polarity of the components decreases, the time spent in the column increases. Thus, a separation of components is achieved based on polarity. The addition of micelles to the mobile phase introduces a third phase into which the solutes may partition.
Sources: en.wikipedia.org
=== The El Ballouti clan === The El Ballouti clan is based in Antwerp, Belgium and led by drug lord Othman El Ballouti. Originally from Al Hoceïma, Othman grew up in the district of Borgerhout, and from a very early age he regularly visited the Port of Antwerp. With the goal of never getting caught by the police, he trafficked thousands of euros in narcotics every day. The newspaper De Volkskrant describes: "Othman climbed the containers and knew how to calculate very well. He quickly stopped climbing the containers by establishing his own gang who did the climbing instead." Othman later on emigrated to Dubai, where he acquired 4 Villas. He also owns an apartment in the famous Address Residence Sky View which is worth 1.5 million euros, alongside six other luxury homes with a total value of around €8.5 million. This information was published by the OCCRP (Organised Crime and Corruption Reporting Project) after he escaped during an arrest at the Zaventem airport in Brussels, in 2016. The Belgian authorities discovered that Othman El Ballouti has a net worth of at least €100 million, a number that ranks him amongst the richest Belgians in the country. The El Ballouti clan is now considered as one of the largest drug trafficking networks in Belgium, and they are also considered to be one of the 5 Moroccan drug clans who control the cocaine trade in the port of Antwerp.
=== Analysis === The interaction between metal ions and peptides are typically studied in solution using spectroscopic or electrochemical methods. Amongst which are circular dichroism (CD), nuclear magnetic resonance (NMR) spectroscopy, cyclic voltammetry, and mass spectrometry (MS).
== External links == Fibronectin, an Extracellular Adhesion Molecule The Fibronectin Protein Fibronectin at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Fibronectin molecular interactions Overview of all the structural information available in the PDB for UniProt: P02751 (Human Fibronectin) at the PDBe-KB. Overview of all the structural information available in the PDB for UniProt: P11276 (Mouse Fibronectin) at the PDBe-KB.
Baclofen or tizanidine are sometimes used as an alternative to benzodiazepines. Tizanidine has been found to have superior tolerability compared to diazepam and baclofen. Benzodiazepines are also used to treat the acute panic caused by hallucinogen intoxication. Benzodiazepines are also used to calm the acutely agitated individual and can, if required, be given via an intramuscular injection. They can sometimes be effective in the short-term treatment of psychiatric emergencies such as acute psychosis as in schizophrenia or mania, bringing about rapid tranquillization and sedation until the effects of lithium or neuroleptics (antipsychotics) take effect. Lorazepam is most commonly used but clonazepam is sometimes prescribed for acute psychosis or mania; their long-term use is not recommended due to risks of dependence. Further research investigating the use of benzodiazepines alone and in combination with antipsychotic medications for treating acute psychosis is warranted. Clonazepam, a benzodiazepine, is used to treat many forms of parasomnia. Rapid eye movement behavior disorder responds well to low doses of clonazepam. Restless legs syndrome can be treated using clonazepam as a third line treatment option as the use of clonazepam is still investigational. Benzodiazepines are sometimes used for obsessive–compulsive disorder (OCD), although they are generally believed to be ineffective for this indication. Effectiveness, however, was found in one small study. Benzodiazepines can be considered as a treatment option in treatment resistant cases.
== History == In a multi-center, randomized trial in participants with active Graves' ophthalmopathy, teprotumumab was more effective than placebo. In February 2019, Horizon announced results from a Phase III confirmatory trial evaluating teprotumumab for the treatment of active thyroid eye disease (TED). The study met its primary endpoint, showing more participants treated with teprotumumab compared with placebo had a meaningful improvement in proptosis, or bulging of the eye: 82.9% of teprotumumab participants compared to 9.5% of placebo participants achieved the primary endpoint of a 2 mm or more reduction in proptosis (p<0.001). Proptosis is the main cause of morbidity in TED. All secondary endpoints were also met and the safety profile was consistent with the Phase II study of teprotumumab in TED. In July 2019, Horizon submitted a biologics license application to the US Food and Drug Administration (FDA) for teprotumumab for the treatment of active thyroid eye disease. Teprotumumab was first investigated for the treatment of solid and hematologic tumors, including breast cancer, Hodgkin's and non-Hodgkin's lymphoma, non-small cell lung cancer, and sarcoma. Teprotumumab-trbw was approved based on the results of two clinical trials (Trial 1/ NCT01868997 and Trial 2/ NCT03298867) of 170 subjects with active TED who were randomized to either receive teprotumumab-trbw or a placebo.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.